# Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

> **NCT02296918** · PHASE1 · COMPLETED · sponsor: **Acerta Pharma BV** · enrollment: 69 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Prolymphocytic Leukemia

## Interventions

- **DRUG:** acalabrutinib
- **DRUG:** Obinutuzumab
- **DRUG:** Venetoclax
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02296918
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-22
- **Primary completion:** 2021-08-20
- **Final completion:** 2025-10-22
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02296918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02296918, "Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02296918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*